What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
|
|
- Charleen Watson
- 5 years ago
- Views:
Transcription
1 What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
2
3 Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent disease progression Prevent and treat exacerbations Reduce mortality Reduce symptoms Reduce risk
4 GOLD 2018: Symptoms and exacerbation risk should be assessed to determine appropriate treatment 1. Diagnose COPD and determine the severity of airflow limitation (GOLD Grade 1 4) using spirometry 2. Determine GOLD Group (A D) and subsequent appropriate pharmacological treatment by assessing symptoms and exacerbation history (including prior hospitalizations) Spirometrically confirmed diagnosis Assessment of airflow limitation Assessment of symptoms/ risk of exacerbations Exacerbation history Grade FEV 1 (% pred.) 1 80 >2 or 1 leading to hospitalization C D Post-bronchodilator FEV 1 /FVC < or 1 (not leading to hospital admission) A B 4 <30 CAT = COPD Assessment Test; CCQ = Clinical COPD Questionnaire; COPD = chronic obstructive pulmonary disease FEV 1 = forced expiratory volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung Disease mmrc = modified Medical Research Council TH , 31/01/2017 mmrc 0 1 CAT <10 CCQ <1 mmrc 2+ CAT 10+ CCQ 1+
5
6 SPIROMICS : a longitudinal study of ever smokers and never smokers Ever smokers (current of former) had > 20 pack years Respiratory symptoms assessed using the COPD Assessment test (CAT) CAT scores range from 0-40; higher score denotes grater impact. GOLD uses CAT score > 10 as a symptom threshold for considering increase symptoms in choice of treatment regimens N Engl J Med 2016;374:
7 Smokers with symptoms despite preserved pulmonary function have COPD-like exacerbation
8 Symptomatic smokers with preserved pulmonary function have airway wall thickening (left) without emphysema (right)
9 GOLD 2018: therapeutic recommendations by GOLD Group Group C Further exacerbation(s) LAMA + LABA LAMA LABA + ICS Group D Consider roflumilast if FEV 1 <50% pred. and patient has chronic bronchitis Further exacerbation(s) Further exacerbation(s) LAMA LAMA + LABA + ICS LAMA + LABA Consider macrolide Persistent symptoms/further exacerbations LABA + ICS Group A Group B Continue, stop or try alternative class of bronchodilator LAMA + LABA Evaluate effect A bronchodilator Persistent symptoms A long-acting bronchodilator (LABA or LAMA) FEV 1 = forced expiratory volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung Disease ICS = inhaled corticosteroid; LABA = long-acting β 2 -agonist; LAMA = long-acting muscarinic antagonist GOLD 2017 TH , 31/01/2017
10 Agusti A. Ann Am Thorac Soc2013;10: s125-s130
11 Concept of one-treatment-fitall Agusti A. Ann Am Thorac Soc2013;10: s125-s130
12 Oslerian diagnostic label Fails to provide optimal care in a significant number of patients Can increase clinical practice variability and enhance inappropriate prescription of some drugs (e.g ICS) Can contribute to treatment failure and high rates of hospital readmissions Inhibits research progress
13 Principles of precision medicine Agusti A, et al. Eur Respir J 2017;50:
14 Precision medicine The terms precision, personalized, and individualized medicine are often used interchangeably.. Precision medicine is treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient from other patients with similar clinical presentations. Jameson JL, NEJM 2015;372:
15 Precision medicine Goal of improving clinical outcomes for individual patients and minimizing unnecessary side effects for those less likely to have a response to a particular treatment.
16 Examples of precision medicine
17 Agusti A, et al. Eur Respir J 2017;50:
18 Agusti A, et al. Eur Respir J 2017;50:
19
20 COPD COPD is complex and heterogeneous Complex means that they have several components with nonlinear dynamic interactions Heterogeneous indicates that not all of these components are present in all patients or, in a given patient, at all time points
21 Main reasons to make precision medicine in COPD There is variability in the clinical presentation There is no correlation between the different variables at the patient level There are a number of relevant clinical variable associated with outcomes We do have specific therapies for specific patient types There is variability in the clinical response
22 Distribution of the CAT score among the different GOLD 2011 classification Lopez-Campos JL, et al. Int J COPD 2015;10:975-84
23 Distribution of Estimated Annual Rates of Change in FEV 1 over a 3-Year Period in COPD patients Vesbo J, et al N Engl J Med 2011;365:
24 Different COPD cases with similar functional impairment but different radiological expression
25 6MWD (Metres) Number of exacerbations mmrc score SGRQ-C Total score Weak correlation between disease outcome parameters and FEV Post-Dose FEV 1 (% Pred.) Rho=-0.36 p< Post-Dose FEV 1 (% Pred.) Rho=-0.38 p< Post-Dose FEV 1 (% Pred.) Rho=-0.34 p< Post-Dose FEV 1 (% Pred.) Rho=-0.21 p<0.001 Agusti et al. Respir Res 2010
26 Functional response to bronchodilator (Trough FEV1) Donohue JF, et al. Respir Med 2016;112:65-74
27 COPD phenotype Miravitlles M, et al. Arch Bronconeumol 2017 :53;
28 2major criteria or 1major and 2minor criteria should be met.
29 Risk classification in Spainish guideline 2017 Miravitlles M, et al. Arch Bronconeumol 2017 :53;
30 Management Spanish COPD Guideline 2017 Miravitlles M, et al. Arch Bronconeumol 2017 :53;
31 Two-step Algorithm algorithm for treatment for treatment of COPD of COPD Lahousse L, et al. Eur Respir J 2017; 49:
32 Benefit risk balance and its individual determinants with personalised COPD treatment choices Woodruff PG, Agusti A, et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet May 2;385(9979):
33 Asthma-COPD overlap phenotype Clinical importance Identification Phenotype-specific management 1.Increased frequency and severity of exacerbation 2.Faster FEV 1 decline 3.Increased health care utilization 4.Increased comorbidity burden and mortality Guidelines: 2 major criteria or 1 major and 2 minor criteria Major criteria: 1.Very positive bronchodilator test result (increase in FEV 1 15% of predicted and 400 ml) 2.Sputum eosinophilia 3.Personal history of asthma Minor criteria: 1.High total IgE 2.Personal history of atopy 3.Positive bronchodilator test result (increase in FEV 1 12% of predicted and 200 ml) on 2 occasions ICS should be an essential part of management in addition to longacting bronchodilators Address atopy component as indicated
34
35 Diagnosis criteria for ACOS
36 Frequent exacerbator phenotype Clinical importance Identification Phenotype-specific management 1.Faster decline in lung function 2.Increased health care utilization 3.Increased mortality up to 3-fold 4.Increased risk of depressive symptoms 2 or more COPD exacerbations per year Long-acting bronchodilators Inhaled corticosteroids Anti-inflammatory treatment: macrolides, roflumilast, acetylcysteine
37 Upper lobe predominant emphysema phenotype Clinical importance Identification Phenotype-specific management 1.Potentially substantial symptomatic benefit with surgical LVR CT findings consistent with predominant upper lobe emphysema Consider surgical LVR
38 Rapid decliner phenotype Clinical importance Identification Phenotype-specific management 1.High mortality Rapid decline of lung function Relatively younger Poor nutritional status No major comorbidities Early subspecialty and lung transplant evaluation
39 Comorbid phenotype Clinical importance Identification Phenotype-specific management 1.Increased health care utilization 2.Poorer quality of life 3.Increased mortality risk Persistently symptomatic despite comprehensive therapy Symptoms are disproportionate with severity of airway obstruction High comorbidity burden, predominantly cardiovascular Aggressive management of comorbid disease
40 Physical frailty phenotype Clinical importance Identification Phenotype-specific management 1.Higher symptom burden 2.Frequent exacerbations 3.Poor functional capacity 4.Poor disease management self-efficacy Screening: 4MGS (4-meter gait speed) (<0.8 m/s), Timed Up and Go test(tugt) (>10 seconds), Program of Research to Integrate Services for the Maintenance of Autonomy(PRISMA-7) questionnaire (score 3) Diagnosis: Fried criteria, frailty deficit index Pulmonary rehabilitation
41 Emotional frailty phenotype Clinical importance Identification Phenotype-specific management 1.Increased health care utilization 2.Poorer quality of life 3.Poor disease management self-efficacy Depression screen PHQ-2 score >3 points Anxiety screen GAD-2 scale >3 points Fear of breathlessness: Screen with How often during the past 2 weeks did you have a feeling of fear or panic when you had difficulty getting your breath? Comprehensive pulmonary rehabilitation that includes behavioral interventions such as health coaching or cognitive therapy Pharmacological management
42 Eosinophil counts in stable COPD predict exacerbation risk
43 Sensitivity Blood eosinophils as a biomarker of eosinophilic exacerbations in COPD % blood eosinophils AUC=0.85 2% cut off 90% sensitivity & 60% specificity Per cent blood eosinophils Serum IL-5 Serum CCL17 Serum VCAM1 Serum TNF-1B Serum C reactive protein Serum IL-6 Serum TNF-1B Serum amyloid A1 Reference Line Specificity 1.0 Bafadhel M et al. Am J Respir Crit Care Med 2011;184:662-71
44 Mean annual exacerbation rate (events per year during follow-up for each individual) in the COPD population by quartiles of blood eosinophils. Vedel-Krogh S, et al. AM j Respir Crit Care Med 2016;193:965-74
45 Risk of severe and moderate exacerbations in COPD using the cutpoints for blood eosinophils of cells per liter and 3.3% Vedel-Krogh S, et al. AM j Respir Crit Care Med 2016;193:965-74
46 Risk factors of COPD exacerbation Vedel-Krogh S, et al. AM j Respir Crit Care Med 2016;193:965-74
47 Eosinophil and response to corticosteroid in COPD exacerbation
48 Blood eosinophil guided prednisolone therapy for exacerbations of COPD Data taken from the three RCTs Bafadhel M, et al. Eur Respir J 2014;44:
49 Eosinophil and response to ICS in COPD exacerbation
50 ISOLDE study Fluticasone propionate monotherapy was compared with placebo in the 3-year No difference in the rate of decline FEV1 for FP versus placebo ( p=0.16) There was a significant reduction in median yearly exacerbation rate with FP versus placebo (0.99 versus 1.32 ;reduction of 25%; p=0.026) Burge PS, et al. BMJ 2000; 320:
51 Blood eosinophils as a marker of response to ICS in COPD Eo<2% Eo>2%
52 TRISTAN: Study design Study participants FEV % pred FEV 1 /FVC ratio < pack years Exacerbation history Reversibility <10% Double-blind treatment period (52 weeks) n=1465 FP/Sal 500/50 µg BD FP 500 µg BD R Sal 50 µg BD Placebo BD Week -2 Week 0 Week 52 Calverley et.al. Lancet 2003; 361: ICS and LABA stopped Anti-cholinergic could continue Primary end-point Pre-bronchodilator FEV 1 Other end-points Exacerbations SGRQ Symptom scores Nocturnal awakenings
53 Exacerbation rate ratio by eos: TRISTAN post-hoc analysis Patients with EOS 2% have a significant reduction in exacerbations with FP, SAL or FP/SAL vs placebo Barnes et al; Am J Respir Crit Care Med 2015:191;A
54 INSPIRE: Study design Study participants years At least 10 pack years History of exacerbations Post-bronchodilator FEV 1 <50% predicted <10% reversibility At least 2 on mmrc scale n=1323 R Double-blind treatment period (2 years) FP/Sal 500/50 µg BD Tiotropium 18 µg OD Week -2 Week 0 Month 24 30mg prednisolone/day Salmeterol 50 µg BD Wedzicha et.al. Am J Respir Crit Care Med 2008;177: Primary end-point Rate of healthcare utilisation exacerbations Other end-points SGRQ Post-bronch FEV 1 Mortality
55 Exacerbation rate by EOS: INSPIRE post-hoc analysis Patients with EOS 2% have significantly greater exacerbation reduction with FP/Sal vs tiotropium Adapted from Barnes et al; Am J Respir Crit Care Med 2015:191;A3975
56 Blood Eosinohils counts, exacerbations, and response inhaled fluticasone furoate /vilanterol in COPD Pascoe S, et al. Lancet Respir Med 2015;3:
57 Expected excess incidence of hospitalization for COPD exacerbation and pneumonia per 100 patients treated with ICS for 1 year Suissa S. et al. Chest 2017
58 Single inhaler triple therapy versus ICS/LABA for COPD (TRILOGY) FEV1 mean change from baseline Singh D, et al. Lancet 2016;388:963-73
59 Single inhaler triple therapy versus ICS/LABA for COPD (TRILOGY) :SGRQ Singh D, et al. Lancet 2016;388:963-73
60 Single inhaler triple therapy versus ICS/LABA for COPD (TRILOGY) moderate and severe exacerbation Singh D, et al. Lancet 2016;388:963-73
61
62
63
64 Targeting eosinophilic inflammation in the airway Barn PJ. J Allergy Clin Immunol 2015;136:531-45
65 Targeting neutrophilic inflammation in the airway Barn PJ. J Allergy Clin Immunol 2015;136:531-45
66 Conclusions Approach to treatment according to clinical phenotypes represents a significant change in management COPD From treatment focused onto more personalised approach directed by clinical feature New studies need to incorporate subgroup analysis of response by particular phenotypes to investigate the response to therapy The results of these trials will help to personalised treatment for this complex disease
67 Questions
Changing Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationAdvancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy Increasing understanding of COPD and the effect on guideline evolution. GOLD
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationCOPD or not COPD, that is the question.
COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationAdjunct Associate Professor Robert Young
Adjunct Associate Professor Robert Young General Physician Auckland City Hospital 7:00-7:55 GlaxoSmithKline Breakfast Session - COPD New approaches in the management of COPD Dr Robert Young BMedSc MBChB
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationUPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures
More informationBlood eosinophil count: a biomarker of an important treatable trait in patients with airway disease
EDITORIAL COPD Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease Ian D. Pavord 1 and Alvar Agusti 2 Affiliations: 1 Respiratory Medicine Unit, Nuffield
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationDr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective
Dr Stephen Child General Physician Auckland 14:20-14:40 Secondary Care Perspective Wheeze Witchery Stephen Child MD, FRACP, FRCPC General Physician Respiratory Interest Director of Clinical Training Auckland
More informationShaping a Dynamic Future in Respiratory Practice. #DFResp
Shaping a Dynamic Future in Respiratory Practice #DFResp www.dynamicfuture.co.uk Inhaled Therapy in COPD: Past, Present and Future Richard Russell Chest Physician West Hampshire Integrated Respiratory
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationCOPD: From Phenotypes to Endotypes. MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI
COPD: From Phenotypes to Endotypes MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI Presenter Disclosures MeiLan K. Han Consulting Research support Novartis
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationClinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene
Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K.
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationGOLD 2017: cosa c è di nuovo
GOLD 2017: cosa c è di nuovo Antonio Spanevello Università degli Studi dell Insubria, Varese Dipartimento di Medicina e Chirurgia Istituti Clinici Scientifici Maugeri, IRCCS, Tradate Dipartimento di Medicina
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationDisclosures. Update on COPD & Asthma. Update on the Management of COPD. No Pharma Disclosures. NHLBI - Asthma Clinical Research Network
Update on COPD & Asthma Michael C. Peters, M.D. MAS Division of Pulmonary & Critical Care Medicine Cardiovascular Research Institute University of California San Francisco UCSF Primary Care Medicine San
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationOptimum treatment for chronic obstructive pulmonary disease exacerbation prevention
Commentary Page 1 of 5 Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention Pradeep Karur, Dave Singh Centre for Respiratory Medicine and Allergy, Medicines Evaluation Unit,
More informationUNDERSTANDING COPD MEDIA BACKGROUNDER
UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationThe Journal Club: COPD Exacerbations
252 The Journal Club: COPD Exacerbations Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club The Journal Club: COPD Exacerbations Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations:
More informationChanging Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?
New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? Conflict of Interest Statement 2018 Speakers Bureau Astra Zeneca Boehringer Ingelheim Genentech Sunovion Ron Balkissoon MD DIH
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationResearch Review. Salmeterol/fluticasone propionate (Seretide ) in COPD. Extended listing for salmeterol/fluticasone propionate in COPD
Research Review Salmeterol/fluticasone propionate (Seretide ) in COPD Extended listing for salmeterol/fluticasone propionate in COPD In New Zealand, salmeterol/fluticasone propionate (SFC) (Seretide )
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationCOPD. Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012
COPD Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012 Attitude It is a disease on which a good deal of wholly, unmerited
More informationConfronting the Challenges of COPD. What is New in The Approaches to Diagnosis, Treatment, and Patient Outcomes
Confronting the Challenges of COPD What is New in The Approaches to Diagnosis, Treatment, and Patient Outcomes COPD Definition GOLD: Global Initiative for Chronic Obstructive Lung Disease Common, preventable,
More informationROBERTO P. BENZO, MD, MS
COPD PHENOTYPES ROBERTO P. BENZO, MD, MS DIRECTOR, MINDFUL BREATHING LABORATORY MAYO CLINIC ROCHESTER, MN Dr. Benzo is the founding director of the Breathing and Behavior Laboratory, which develops and
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 19 February 2009 Doc. Ref. EMEA/CHMP/EWP/8197/2009 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CONCEPT
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationTHE COPD-ASTHMA OVERLAP SYNDROME
THE COPD-ASTHMA OVERLAP SYNDROME NICOLA A. HANANIA, MD, MS, FRCP(C), FCCP, FACP ASSOCIATE PROFESSOR OF MEDICINE DIRECTOR OF ASTHMA & COPD CLINICAL RESEARCH CENTER BAYLOR COLLEGE OF MEDICINE HOUSTON, TX
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More informationNuovi farmaci in sviluppo per la BPCO
PNEUMOLOGIA 2018 MILANO, 14 16 GIUGNO 2018 CENTRO CONGRESSI PALAZZO DELLE STELLINE Nuovi farmaci in sviluppo per la BPCO Leonardo M. Fabbri, MD, FERS Professor of Respiratory and Internal Medicine, University
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationDisease progression in COPD:
Disease progression in COPD: What is it? How should it be measured? Can it be modified? Professor Paul Jones MD, PhD, FERS Emeritus Professor of Respiratory Medicine; St George s, University of London
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationRoflumilast: Οι κλινικές μελέτες
Roflumilast: Οι κλινικές μελέτες Επαμεινώνδας Ν. Κοσμάς Δ/ντής Πνευμονολογικού Τμήματος Νοσοκομείου Metropolitan PDE4 PLAYS AN IMPORTANT ROLE IN INFLAMMATION PDE4 inhibition P P P PDE4 P Adapted from Rabe
More informationSydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK. Affiliated with
Sydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK Affiliated with COPD and Comorbidities Norbert Berend Professor Emeritus University of Sydney Head, Respiratory Research The George Institute
More informationAddressing Undertreatment
Objectives TOWARD BETTER COPD OUTCOMES The Critical Role of Primary Care for Early Diagnosis and Guideline-directed Management Keith Robinson, MD, MS, FCCP Pulmonary Physicians of South Florida, LLC Fusion
More informationCirculating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study
ORIGINAL ARTICLE COPD Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study Yochai Adir 1, Omar Hakrush 1, Michal Shteinberg 1, Sonia Schneer 1 and Alvar Agusti
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationSupplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationSGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life
SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective
More informationModern Management of COPD.
Modern Management of COPD. Associate Professor Robert Young BMedSc, MBChB, DPhil (Oxon), FRACP, FRCP Department of Medicine, Auckland City Hospital and University of Auckland, New Zealand 2 Sponsor Disclaimer
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationGOLD UPDATE on COPD and the Importance of Accurate Dyspnea Evaluation
GOLD UPDATE on COPD and the Importance of Accurate Dyspnea Evaluation George Anderson, PhD Sr. Medical Science Liaison MA-AZAP ML-4006-US-0212 Approved 11/16 Glob al Strategy for the Diagnosis, Management,
More informationLong Term Care Formulary RS -29
RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)
More informationJournal of the COPD Foundation. Journal Club. Chronic Obstructive Pulmonary Diseases:
85 Journal Club Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations: inhaled corticosteroid, ICS; long acting β 2 -agonist,
More informationPresenter Disclosure Information
12:45 1:3 pm Improving Outcomes in COPD SPEAKER Michael Campos, MD Presenter Disclosure Information The following relationships exist related to this presentation: Michael Campos, MD: No financial relationships
More informationPharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08
Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationroflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationManagement of COPD Updates and Evidence
Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD http://www.fpnotebook.com/_media/lungxsgraybb962.gif
More informationRe-Submission. roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd. Published 11 September
Re-Submission roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd 4 August 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationJournal of the COPD Foundation. Impact of the IMPACT Trial Ron Balkissoon, MD, MSc, DIH, FRCPC 1. Chronic Obstructive Pulmonary Diseases: Journal Club
221 Journal Club: The IMPACT Trial Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club Impact of the IMPACT Trial Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations: Global
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
10:50-11:50am Case Studies in Pulmonary Medicine for the Primary Care Clinician SPEAKERS Timothy J. Scialla, MD Common Shortcuts/Common Misperceptions Smoking + Dyspnea = COPD Hospitalization for cough
More informationObjectives. Advances in Managing COPD Patients
4:45 5:30pm Advances in Managing Patients SPEAKER Nicola Hanania, MD, FCCP, FRCP, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Nicola Hanania, MD,
More informationAsthma and COPD. Health Net Provider Educational Webinar
Asthma and COPD Health Net Provider Educational Webinar AstraZeneca 2015 Disclosures Presenters today are employed by Astra Zeneca and have nothing to disclose. This presentation is free from bias. 2 Objectives
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationYuriy Feschenko, Liudmyla Iashyna, Ksenia Nazarenko and Svitlana Opimakh
2018; 7(1): 74-78 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(1): 74-78 2018 TPI www.thepharmajournal.com Received: 11-11-2017 Accepted: 12-12-2017 Yuriy Feschenko Liudmyla Iashyna
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More information